Tuesday, June 30, 2020
Sunday, June 28, 2020
Friday, June 26, 2020
Wednesday, June 24, 2020
Monday, June 22, 2020
Saturday, June 20, 2020
Thursday, June 18, 2020
Wednesday, June 17, 2020
Monday, June 15, 2020
Saturday, June 13, 2020
Thursday, June 11, 2020
Wednesday, June 10, 2020
Tuesday, June 9, 2020
Monday, June 8, 2020
Saturday, June 6, 2020
Thursday, June 4, 2020
Neal D. Shore, MD, FACS Discusses Impact, Treatment Implications of the Phase III HERO Trial | Cancer Network
Neal D. Shore, MD, FACS Discusses Impact, Treatment Implications of the Phase III HERO Trial | Cancer Network: The Carolina Urologic Research Center expert discusses the benefits of oral relugolix for patients with prostate cancer.
Detection and dynamics of circulating tumor cells in patients with high-risk prostate cancer treated with radiotherapy and hormones: a prospective phase II study | Radiation Oncology | Full Text
Detection and dynamics of circulating tumor cells in patients with high-risk prostate cancer treated with radiotherapy and hormones: a prospective phase II study | Radiation Oncology | Full Text: Circulating tumor cells (CTCs) are an established prognostic marker in castration-resistant prostate cancer but have received little attention in localized high-risk disease. We studied the detection rate of CTCs in patients with high-risk prostate cancer before and after androgen deprivation therapy and radiotherapy to assess its value as a prognostic and monitoring marker. We performed a prospective analysis of CTCs in the peripheral blood of 65 treatment-naïve patients with high-risk prostate cancer. EpCAM-positive CTCs were enumerated using the CELLSEARCH system at 4 timepoints. A cut off of 0 vs ≥ 1 CTC/7.5 ml blood was defined as a threshold for negative versus positive CTCs status. CTCs were detected in 5/65 patients (7.5%) at diagnosis, 8/62 (12.9%) following neoadjuvant androgen deprivation and 11/59 (18.6%) at the end of radiotherapy, with a median CTC count/7.5 ml of 1 (range, 1–136). Only 1 patient presented a positive CTC result 9 months after radiotherapy. Positive CTC status (at any timepoint) was not significantly associated with any clinical or pathologic factors. However, when we analyzed variations in CTC patterns following treatment, we observed a significant as
Wednesday, June 3, 2020
Tuesday, June 2, 2020
High‐throughput screen identifies 5‐HT receptor as a modulator of AR and a therapeutic target for prostate cancer - Itsumi - - The Prostate - Wiley Online Library
High‐throughput screen identifies 5‐HT receptor as a modulator of AR and a therapeutic target for prostate cancer - Itsumi - - The Prostate - Wiley Online Library: Background
Eradication of persistent androgen receptor (AR) activity in castration‐resistant prostate cancer may be a promising strategy to overcome castration resistance. We aimed to identify novel...
Eradication of persistent androgen receptor (AR) activity in castration‐resistant prostate cancer may be a promising strategy to overcome castration resistance. We aimed to identify novel...
Monday, June 1, 2020
Subscribe to:
Posts (Atom)